AVI BioPharma Announces Partner’s Advance In Cardiovascular Program

AVI BioPharma, Inc. (NASDAQ: AVII) announced that its partner in its cardiovascular program, Global Therapeutics, the cardiology unit of Cook Medical, has received CE Mark approval for a new cobalt chromium bare metal stent. The device, the Global Therapeutics GTX Coronary Stent System, is also the platform for a breakthrough drug-eluting stent (DES) technology which utilizes AVI-5126, developed by AVI.

More: continued here

Filed under: Cardiovascular on June 19th, 2008